Pixl
2 known investors
Pixl Bio develops human iPSC-derived cell models (hepatocytes, stellates, organoids, including CRISPR-edited disease models) combined with high-content imaging and AI-driven phenomics to generate predictive biology data for drug discovery, toxicology, and safety assessment. It offers models, cell-painting phenomics workflows, and custom end-to-end research services to biopharma companies.